Nichole Tucker | Authors

Articles

Anlotinib Improves PFS in RAS/BRAF Wildtype-Positive Metastatic Colorectal Cancer

January 15, 2021

Treatment with the multi-target tyrosine kinase inhibitor anlotinib led to a significant improvement in progression-free survival along with a tolerable and manageable safety profile in Chinese patients with refractory metastatic colorectal cancer. according to results from the phase 3 ALTER0703 trial.

FDA Approves Crizotinib in Pediatric ALK+ Relapsed or Refractory Systemic ALCL

January 14, 2021

The FDA granted approval to the antineoplastic tyrosine kinase inhibitor, crizotinib, as treatment of pediatric patients 1 year of age and older and young adults with ALK alteration-positive relapsed or refractory systemic anaplastic large cell lymphoma.

Zotiraciclib Plus Temozolomide Shows Early PFS Benefit in Recurrent Gliomas

January 14, 2021

The investigational, potent, oral CDK9 inhibitor, zotiraciclib in combination with temozolomide, demonstrated early improvement in progression-free survival as treatment of patients with recurrent high-grade gliomas, meeting the primary end point of the phase 1B 17-C-0009 trial clinical trial.